Itolizumab
Psoriasis
ApprovedCommercial
Key Facts
About Biocon
Founded in 1978 by Kiran Mazumdar-Shaw, Biocon has evolved from a garage startup into Asia's premier biotechnology enterprise with a focus on affordable healthcare solutions. The company operates through three key subsidiaries: Biocon Biologics (biosimilars), Biocon Pharma (generics), and Syngene (research services), serving patients in over 120 countries. Biocon has established itself as a pioneer in insulin manufacturing and biosimilar development, with multiple products approved by stringent regulatory authorities including FDA and EMA.
View full company profileTherapeutic Areas
Other Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| Taltz (ixekizumab) | Eli Lilly | Approved |
| Ilumya (tildrakizumab) | Sun Pharmaceutical | Approved |
| SCD-044 | Sun Pharmaceutical | Phase 2 |
| SCD-105 | SPARC | Phase 2 |
| IMP731 | Immutep | Phase 1/Ib |
| CYPS317 | FibroBiologics | Discovery |